Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
GPX7
REST API REST API
Homo sapiens
GPX7 is differentially expressed in 237 experiments: 134 organism parts: blood, cervix, ... (132 more);, 175 disease states: normal, acute myeloid leukemia, ... (173 more);, 90 cell types 470 cell lines 22 compound treatments and 62 other conditions.
Synonyms GPX6, FLJ14777, NPGPx
Orthologs PHGPx (Drosophila melanogaster)   F6RM35_CIOIN (Ciona intestinalis)   CG15116 (Drosophila melanogaster)   Gpx7 (Mus musculus)   E1C697_CHICK (Gallus gallus)   GPX1 (Saccharomyces cerevisiae)   gpx7 (Danio rerio)   GPX7_BOVIN (Bos taurus)   Gpx7 (Rattus norvegicus)   HYR1 (Saccharomyces cerevisiae)   gpx7 (Xenopus laevis)   GPX2 (Saccharomyces cerevisiae)   GPX7 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term oxidoreductase activity, response to oxidative stress, glutathione peroxidase activity, antioxidant activity, extracellular region, oxidation-reduction process
InterPro Term Glutathione_peroxidase, Glut_perox_Gpx7, AhpC/TSA
UniProt Accession Q96SL4
Search EB-eye ENSG00000116157
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-803, E-GEOD-6573, E-GEOD-7540, E-GEOD-3526, ... (25 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-3860, E-GEOD-4525, E-GEOD-18005, E-GEOD-19397, ... (36 experiments)

Factor Value U/D Experiments
HepG2
3
E-GEOD-21154, E-MTAB-37, E-GEOD-7307
Jurkat
2
E-GEOD-1880, E-MEXP-2197
K562
2
E-MTAB-37, E-GEOD-24147
SW480
2
E-GEOD-18005, E-MTAB-37
T84
2
E-GEOD-1474, E-MTAB-37
GM18951
1
E-GEOD-19466
464 more value(s).


Cell type

studied in E-GEOD-21668, E-GEOD-19397, E-GEOD-3920, E-MEXP-66, E-GEOD-4219, ... (47 experiments)

Factor Value U/D Experiments
CD14+ monocyte
3
E-AFMX-5, E-TABM-145, E-MEXP-1600
CD71+ early erythroid
2
E-AFMX-5, E-TABM-145
721 B lymphoblast
2
E-AFMX-5, E-TABM-145
endothelial cell
1
2
E-GEOD-19240, E-GEOD-3920, E-GEOD-96
leydig cell
1
E-MTAB-25
epidermoid
1
E-GEOD-19397
84 more value(s).


Disease state

studied in E-GEOD-3307, E-MTAB-62, E-GEOD-5418, E-GEOD-1825, E-GEOD-6731, ... (49 experiments)

Factor Value U/D Experiments
glioblastoma
3
E-GEOD-4290, E-MTAB-62, E-GEOD-4412
septic shock
2
E-GEOD-9692, E-GEOD-8121
head and neck squamous cell carcinoma
2
E-GEOD-6631, E-GEOD-2379
acute promyelocytic leukemia
2
E-GEOD-995, E-MTAB-62
colon carcinoma
2
E-MTAB-62, E-MTAB-37
lung adenocarcinoma
2
E-MTAB-62, E-MTAB-37
169 more value(s).


Compound treatment

studied in E-GEOD-5258, E-GEOD-15205, E-TABM-782, E-GEOD-697, E-GEOD-5824, ... (18 experiments)

Factor Value U/D Experiments
saline
1
E-GEOD-3026
TNF
1
E-GEOD-15205
HMB-PP (phosphoantigen)
1
E-MEXP-1601
TTA
1
E-MEXP-2590
dimethyl sulfoxide
1
E-GEOD-5824
rapamycin
1
E-GEOD-5824
16 more value(s).


Age at onset

studied in E-GEOD-21521

Factor Value U/D Experiments
LT6
1
E-GEOD-21521


Agent
studied in E-GEOD-19519

Biosource provider
studied in E-MTAB-37, E-GEOD-14359

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21589, E-GEOD-16363 ... (5 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-MEXP-1251, E-GEOD-21589, ... (7 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-20033, E-GEOD-4667, E-MEXP-2283, E-MTAB-62

Disease staging
studied in E-GEOD-19743, E-GEOD-7788, E-GEOD-3325, E-TABM-147, E-GEOD-19665, ... (6 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-7011, E-GEOD-7578, E-GEOD-20847, E-MEXP-563

Genotype
studied in E-TABM-1029, E-GEOD-22056, E-GEOD-22593, E-TABM-868, E-MEXP-1648, ... (6 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-MEXP-2657, E-GEOD-20504, E-GEOD-837, E-MEXP-2146 ... (5 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Individual
studied in E-TABM-325, E-MTAB-197, E-MEXP-2069, E-GEOD-1926, E-MEXP-1648, ... (32 experiments)

Injury
studied in E-GEOD-19743

Labeling
studied in E-LGCL-5

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540

Organism status
studied in E-GEOD-19188

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-1309, E-GEOD-1657

Population
studied in E-MTAB-197, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246 ... (5 experiments)

Replicate
studied in E-GEOD-10797

RNAi
studied in E-MEXP-101, E-GEOD-3697, E-MEXP-1857

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743

Sex
studied in E-GEOD-19069, E-GEOD-7307

Stimulation
studied in E-GEOD-4883, E-GEOD-20114

Strain or line
studied in E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Test result
studied in E-GEOD-1926

Treatment
studied in E-GEOD-16837, E-GEOD-19246, E-GEOD-19815, E-GEOD-12198

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments 99 146
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-1561, E-GEOD-4922

Processing time: 0.305 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM